Post partum haemorrhage and the WOMAN Trial

1.Hogan MC, Foreman KJ, Naghavi M, et al. Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet 2010; 375: 1609-23.
2.Ronsmans C, Graham WJ. Maternal mortality: who, when, where, and why. Lancet 2006; 368: 1189200.
3.WHO Recommendations for the prevention of postpartum haemorrhage. Geneva: World Health Organisation, 2007.
4.Okamoto S, Hijikata-Okunomiya A, Wanaka K, Okada Y, Okamoto U. Enzyme controlling medicines: introduction. Semin Thromb Hemost 1997; 23: 493501.
5.Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007; 4: CD001886.
6.CRASH-2: tranexamic acid and trauma patients. Executive Summary. Launched in June, 2010 [Internet]. Accessed in July, 2010 from http://www.thelancet.com/crash-2
7.CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet, 2010 376, Issue 9734: p23 - 32
8.Ferrer P, Roberts I, Sydenham E, Blackhall K, Shakur H. Anti-fi brinolytic agents in postpartum haemorrhage: a systematic review. BMC Pregnancy Childbirth 2009; 9: 29.
9.Shakur H, Elbourne D, Gulmezoglu M, et al. The WOMAN Trial (World Maternal Antifi brinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials 2010; 11: 40.